″ Arguably, donors could have a bigger impact by donating to an advocacy group than by donating to Go Give One, though this field is so new that it’s hard to know for sure.
For donors who prefer to invest in advocacy, Dodson and Glassman both recommended three groups: Global Citizen, the ONE Campaign, and the Pandemic Action Network.
“To the extent that advocacy movements help reduce the political cost of doing the right thing and create political benefits, I think it’s a good thing,” Glassman said. “And the amounts of money at stake that they could potentially influence are large, especially in the United States.” ”
My immediate reaction is that that depends on the specific objectives of the advocacy organizations, as well as who they’re aiming to influence.
For example, the article mentions the patent waiver a lot. While this is (I think) a point of difference between Manya and me, I’m currently unsure (50-50 split, in fact) about the sign of the effect of the patent waiver, and pretty convinced the magnitude is small (and that it obscures the deeper problems with vaccine supply).
Did you consider advocacy, as mentioned in a recent Future Perfect piece (talking about vaccine supply generally, not specific to India): https://www.vox.com/future-perfect/22440986/covax-challenges-covid-19-vaccines-global-inequity
″ Arguably, donors could have a bigger impact by donating to an advocacy group than by donating to Go Give One, though this field is so new that it’s hard to know for sure.
For donors who prefer to invest in advocacy, Dodson and Glassman both recommended three groups: Global Citizen, the ONE Campaign, and the Pandemic Action Network.
“To the extent that advocacy movements help reduce the political cost of doing the right thing and create political benefits, I think it’s a good thing,” Glassman said. “And the amounts of money at stake that they could potentially influence are large, especially in the United States.” ”
Thanks for the link! I will look into this soon.
My immediate reaction is that that depends on the specific objectives of the advocacy organizations, as well as who they’re aiming to influence.
For example, the article mentions the patent waiver a lot. While this is (I think) a point of difference between Manya and me, I’m currently unsure (50-50 split, in fact) about the sign of the effect of the patent waiver, and pretty convinced the magnitude is small (and that it obscures the deeper problems with vaccine supply).